Shares of Intra-Cellular Therapies Inc. (NASDAQ:ITCI) have been assigned an average recommendation of “Hold” from the nine analysts that are currently covering the firm. One investment analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and five have issued a buy recommendation on the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $39.83.

ITCI has been the subject of several recent research reports. Piper Jaffray Cos. reissued an “overweight” rating and set a $22.00 price target on shares of Intra-Cellular Therapies in a report on Tuesday, November 1st. Leerink Swann reissued a “buy” rating and set a $95.00 price target on shares of Intra-Cellular Therapies in a report on Thursday, August 11th. RBC Capital Markets reissued an “outperform” rating and set a $49.00 price target (down previously from $74.00) on shares of Intra-Cellular Therapies in a report on Friday, September 30th. Zacks Investment Research raised Intra-Cellular Therapies from a “sell” rating to a “hold” rating in a report on Friday, November 11th. Finally, SunTrust Banks Inc. lowered Intra-Cellular Therapies from a “buy” rating to a “neutral” rating and cut their price target for the company from $60.00 to $15.00 in a report on Thursday, September 29th.

In other news, Director Christopher D. Alafi bought 34,000 shares of the firm’s stock in a transaction that occurred on Monday, November 14th. The shares were bought at an average cost of $14.50 per share, for a total transaction of $493,000.00. Following the completion of the transaction, the director now owns 730,529 shares of the company’s stock, valued at $10,592,670.50. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 19.80% of the stock is owned by corporate insiders.

Large investors have recently bought and sold shares of the company. Price T Rowe Associates Inc. MD increased its stake in Intra-Cellular Therapies by 5,767.6% in the third quarter. Price T Rowe Associates Inc. MD now owns 563,702 shares of the biopharmaceutical company’s stock worth $8,591,000 after buying an additional 554,095 shares in the last quarter. Credit Suisse AG increased its stake in Intra-Cellular Therapies by 3.9% in the third quarter. Credit Suisse AG now owns 28,001 shares of the biopharmaceutical company’s stock worth $426,000 after buying an additional 1,058 shares in the last quarter. Baker BROS. Advisors LP purchased a new stake in Intra-Cellular Therapies during the third quarter worth approximately $9,284,000. Hillhouse Capital Management Ltd. purchased a new stake in Intra-Cellular Therapies during the third quarter worth approximately $15,240,000. Finally, The Manufacturers Life Insurance Company purchased a new stake in Intra-Cellular Therapies during the third quarter worth approximately $342,000. Institutional investors own 67.13% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This article was originally published by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are reading this article on another website, it was stolen and reposted in violation of U.S. and international copyright law. The original version of this article can be viewed at https://www.thecerbatgem.com/2016/11/27/intra-cellular-therapies-inc-itci-receives-39-83-average-pt-from-brokerages.html.

Intra-Cellular Therapies (NASDAQ:ITCI) opened at 13.66 on Tuesday. The company’s 50 day moving average price is $13.23 and its 200-day moving average price is $32.05. The stock’s market capitalization is $591.04 million. Intra-Cellular Therapies has a one year low of $10.80 and a one year high of $59.76.

Intra-Cellular Therapies (NASDAQ:ITCI) last issued its quarterly earnings data on Wednesday, November 9th. The biopharmaceutical company reported ($0.70) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.84) by $0.14. The firm earned $4.36 million during the quarter, compared to the consensus estimate of $0.04 million. During the same period in the previous year, the firm earned ($0.91) EPS. The business’s revenue was up NaN% on a year-over-year basis. Analysts expect that Intra-Cellular Therapies will post ($2.84) earnings per share for the current year.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS).

5 Day Chart for NASDAQ:ITCI

Receive News & Stock Ratings for Intra-Cellular Therapies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies Inc. and related stocks with our FREE daily email newsletter.